UniProt Q9UKE5 · PDB · AlphaFold · Substrate: LRRKtide · Clone: Catalytic (1-367)high-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Bosutinib | 99.6% | 0.4% | 87.22 | 0.555 |
| 2 | Ponatinib | 99.4% | 0.6% | 78.23 | 0.534 |
| 3 | Pacritinib | 99.2% | 0.8% | 88.64 | 0.452 |
| 4 | Axitinib | 99.0% | 1.0% | 93.23 | 0.688 |
| 5 | Neratinib | 98.9% | 1.1% | 93.18 | 0.597 |
| 6 | Gilteritinib | 98.8% | 1.2% | 88.97 | 0.506 |
| 7 | Sunitinib | 98.3% | 1.7% | 91.73 | 0.524 |
| 8 | Lenvatinib | 97.2% | 2.8% | 97.74 | 0.726 |
| 9 | Pazopanib | 95.8% | 4.2% | 97.49 | 0.672 |
| 10 | Nintedanib | 95.5% | 4.5% | 90.23 | 0.608 |
| 11 | Vemurafenib | 94.4% | 5.6% | 96.49 | 0.598 |
| 12 | Midostaurin | 92.8% | 7.2% | 78.64 | 0.500 |
| 13 | Tivozanib | 91.5% | 8.5% | 92.42 | 0.673 |
| 14 | Defactinib | 87.5% | 12.5% | 92.68 | 0.450 |
| 15 | Erdafitinib | 83.0% | 17.0% | 95.71 | 0.737 |
| 16 | Osimertinib | 81.3% | 18.7% | 97.24 | 0.733 |
| 17 | Abemaciclib | 79.3% | 20.7% | 91.48 | 0.563 |
| 18 | Alectinib | 79.0% | 21.0% | 95.49 | 0.651 |
| 19 | Dasatinib | 76.4% | 23.6% | 87.97 | 0.699 |
| 20 | Pirtobrutinib | 59.5% | 40.5% | 99.49 | 0.656 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 2.83
- Epithelial log2(TPM+1): 2.14
- Fold change: 0.69
- Status: No significant change
High-confidence drugs
- Lenvatinib — inh 97.2% · KISS 49.51
- Pazopanib — inh 95.8% · KISS 42.38
- Axitinib — inh 99.0% · KISS 42.18
Selectivity landscape vs inhibition on TNIK
Each point is one of the 92 approved drugs; color = inhibition % on TNIK.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…